Addition of lafutidine can improve disease activity and lead to better quality of life in refractory cholinergic urticaria unresponsive to histamine H1 antagonists. Issue 2 (May 2016)

• Record Type: Journal Article
• Authors: Hatakeyama, Mayumi; Fukunaga, Atsushi; Washio, Ken; Ogura, Kanako; Yamada, Yozo; Horikawa, Tatsuya; Nishigori, Chikako
• Is Part Of: Journal of dermatological science. Volume 82:Issue 2(2016:May)
• Page Start: 137
• Page End: 139
• Publication Date: 2016-05
• Subjects: CU cholinergic urticaria -- H1RA H1 receptor antagonists -- H2RA H2 receptor antagonists -- QoL quality of life -- DLQI-J Dermatology Life Quality Index; Cholinergic urticaria -- H2 receptor antagonists -- Lafutidine -- Quality of life; Dermatology -- Periodicals; Skin Diseases -- Periodicals; Dermatologie -- Périodiques; 616.5005
• DOI: 10.1016/j.jdermsci.2016.02.001
• Languages: English
• ISSNs: 0923-1811

Abstract

Highlights: Suitable treatment options except for H1RA are still lacking for severe refractory CU. Addition of lafutidine to H1RA treatment significantly improved urticarial symptoms in severe refractory CU. The DLQI score was markedly improved after the addition of lafutidine to H1RA treatment in severe refractory CU. No adverse events occurred after the addition of lafutidine in severe refractory CU.